Stockreport

Boston Biomedical, Inc. Announces First Patient Dosed in Phase 1 Study of Investigational Agent TP-3654 in Patients with Myelofibrosis

SUMITOMO CHEM UNSP/ADR  (SOMMY) 
NASDAQ:AMEX Investor Relations: sumitomo-chem.co.jp/english/ir
PDF CAMBRIDGE, Mass., April 6, 2020 /PRNewswire/ -- Boston Biomedical, Inc. today announced the first patient has been dosed in a phase 1 study evaluating the investigationa [Read more]